Bladder-Sparing hope: immune combo targets tough bladder cancer

NCT ID NCT07307456

Recruiting now Disease control Sponsor: Changhai Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study tests whether adding an immunotherapy drug (toripalimab) to standard BCG therapy can help people with high-risk bladder cancer avoid bladder removal. About 31 participants will receive the combination after surgery. The main goal is to see if the cancer disappears within 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab (a PD-1 inhibitor) combined with BCG (a tuberculosis vaccine used to stimulate the immune system)
What this could lead to: If this works, it could offer a new way to treat high-risk bladder cancer without removing the bladder, potentially improving quality of life.
What could go wrong: This is a small, early-phase trial with only 31 people. The combination may not work better than standard treatments, and side effects from the immune drug and BCG could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma superficial urinary bladder carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

ChangHai Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.